CymaBay Therapeutics

OverviewSuggest Edit

CymaBay Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare and orphan diseases. The Company's two key clinical development candidates are Seladelpar and Arhalofenate. Seladelpar is a potent, selective, orally active PPARδ agonist currently in development for the treatment of patients with the autoimmune liver disease, primary biliary cholangitis and the epidemic in nonalcoholic SteatoHepatitis. Arhalofenate is a potential urate-lowering anti-flare therapy for gout that is Phase 3 ready. The Company's pipeline also includes additional investigational products and lead candidates for liver and other chronic diseases.

TypePublic
Founded1991
HQNewark, US
Websitecymabay.com

Latest Updates

Employees (est.) (Jan 2019)43(+66%)
Share Price (May 2019)$12.6 (+2%)

Key People/Management at CymaBay Therapeutics

Sujal Shah

Sujal Shah

President and Chief Executive Officer
Pol Boudes

Pol Boudes

Chief Medical Officer
Robert L. Martin

Robert L. Martin

Senior Vice President, Manufacturing and Nonclinical Development
Klara Dickinson

Klara Dickinson

Chief Regulatory and Compliance Officer
Charles A. McWherter

Charles A. McWherter

Senior Vice President and Chief Scientific Officer
Patrick J. OMara

Patrick J. OMara

Senior Vice President, Business Development
Show more

CymaBay Therapeutics Office Locations

CymaBay Therapeutics has an office in Newark
Newark, US (HQ)
7999 Gateway Blvd
Show all (1)

CymaBay Therapeutics Financials and Metrics

CymaBay Therapeutics Revenue

USD

Net income (FY, 2018)

(72.5m)

EBIT (FY, 2018)

(72.5m)

Market capitalization (21-May-2019)

866.2m

Closing stock price (21-May-2019)

12.6

Cash (31-Dec-2018)

49.0m
CymaBay Therapeutics's current market capitalization is $866.2 m.
Annual
USDFY, 2013FY, 2015FY, 2016FY, 2017FY, 2018

General and administrative expense

4.9m8.9m9.6m12.4m14.4m

R&D expense

4.5m17.0m15.9m18.9m58.1m

Operating expense total

9.4m25.9m25.6m31.3m72.5m

EBIT

(9.4m)(25.9m)(25.6m)(21.3m)(72.5m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

General and administrative expense

683.0k2.5m1.7m1.7m2.3m2.2m2.5m2.2m2.1m3.7m3.6m3.4m6.9m

R&D expense

703.0k2.6m4.1m3.8m4.3m4.5m4.4m4.1m3.5m4.0m4.0m9.5m23.9m

Operating expense total

1.4m5.1m5.7m5.5m6.5m6.7m6.9m6.3m5.7m7.7m7.6m12.9m30.8m

EBIT

(1.4m)(5.1m)(5.7m)(5.5m)(6.5m)(6.7m)(6.9m)(6.3m)(5.7m)(2.9m)(7.6m)(12.8m)(30.8m)
Annual
USDFY, 2013FY, 2016FY, 2017FY, 2018

Net Income

(10.1m)(26.7m)(27.6m)(72.5m)

Depreciation and Amortization

55.0k29.0k35.0k105.0k

Accounts Payable

40.0k(109.0k)412.0k662.0k

Cash From Operating Activities

(8.5m)(23.4m)(19.6m)(54.9m)
Quarterly
USDQ1, 2018Q2, 2018

Net Income

(17.0m)(34.5m)

Depreciation and Amortization

12.0k25.0k

Accounts Payable

727.0k25.0k

Cash From Operating Activities

(6.4m)(19.3m)
USDY, 2018

Financial Leverage

1.1 x
Show all financial metrics

CymaBay Therapeutics Blogs

CymaBay Therapeutics Presents Data in Patients with Primary Biliary Cholangitis at DDW 2019

NEWARK, Calif., May 20, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced results related to its seladelpar clinical…

CymaBay Reports First Quarter 2019 Financial Results and Provides Corporate Update

Conference call and webcast today at 4:30p.m. ET NEWARK, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced finan…

CymaBay Therapeutics Announces Multiple Presentations at DDW 2019

NEWARK, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), today announced that multiple abstracts related to its seladelpar clinical development program for the treatment of primary biliary cholangitis (PBC) will be presented in poster sessions at Digestive Disea…

CymaBay Therapeutics to Report First Quarter 2019 Financial Results on Wednesday, May 8

NEWARK, Calif., April 30, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio we…

CymaBay Therapeutics Presents Positive Phase 2 Data for Seladelpar in Patients with Primary Biliary Cholangitis at the International Liver Congress™ 2019

NEWARK, Calif., April 12, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced positive results from its Phase 2 study …

CymaBay Therapeutics Announces Multiple Presentations During The International Liver Conference™ 2019

Oral presentation will feature clinical data for seladelpar in primary biliary cholangitis (PBC) patients with cirrhosis NEWARK, Calif., March 27, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), today announced that multiple seladelpar presentations will be delivered during Th…
Show more

CymaBay Therapeutics Frequently Asked Questions

  • When was CymaBay Therapeutics founded?

    CymaBay Therapeutics was founded in 1991.

  • Who are CymaBay Therapeutics key executives?

    CymaBay Therapeutics's key executives are Sujal Shah, Pol Boudes and Robert L. Martin.

  • How many employees does CymaBay Therapeutics have?

    CymaBay Therapeutics has 43 employees.

  • Who are CymaBay Therapeutics competitors?

    Competitors of CymaBay Therapeutics include Biogen, MyoKardia and Otonomy.

  • Where is CymaBay Therapeutics headquarters?

    CymaBay Therapeutics headquarters is located at 7999 Gateway Blvd, Newark.

  • Where are CymaBay Therapeutics offices?

    CymaBay Therapeutics has an office in Newark.

  • How many offices does CymaBay Therapeutics have?

    CymaBay Therapeutics has 1 office.